Literature DB >> 32835276

SARS-CoV-2 Fulminant Myocarditis.

Jérôme Garot1, Julien Amour2, Théo Pezel1, Firas Dermoch2, Kamel Messadaa2, Marie-Louise Felten2, Valérie Raymond2, Eric Baubillier2, Francesca Sanguineti1, Philippe Garot1,2.   

Abstract

An 18-year-old male without prior medical history developed fulminant myocarditis concomitant to severe COVID-19 pneumonia, which was confirmed using serial cardiac magnetic resonance. This may have important diagnostic, monitoring, and pathogenic implications. (Level of Difficulty: Intermediate.).
© 2020 The Authors.

Entities:  

Keywords:  COVID-19, coronavirus disease-2019; EF, ejection fraction; EGE, early gadolinium enhancement; LGE, late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; SARS-CoV-19, severe acute respiratory syndrome-coronavirus-2019; cardiac magnetic resonance; coronavirus disease 2019; myocarditis

Year:  2020        PMID: 32835276      PMCID: PMC7274592          DOI: 10.1016/j.jaccas.2020.05.060

Source DB:  PubMed          Journal:  JACC Case Rep        ISSN: 2666-0849


An 18-year-old male without prior medical history was admitted for cough, fever (38.5°C), fatigue, and myalgias. From his vital signs, blood pressure was 120/70 mm Hg, heart rate 110 beats/min, he had tachypnoea (22/min), and oxygen saturation was 94% in room air. He had no neurological symptoms. He did not have any past medical history.

Learning Objectives

To make a diagnosis of fulminant myocarditis concomitant with COVID-19 pneumonia. To understand the value of serial cardiac magnetic resonance after myocarditis due to COVID-19.

Differential Diagnosis

Primary differential included community acquired pneumonia, atypical pneumonia, and severe acute respiratory syndrome-coronavirus-2019 (SARS-CoV-19).

Investigations

The reverse transcriptase–polymerase chain reaction assay was positive for COVID-19 on the nasopharyngeal swab whereas chest computed tomography demonstrated diffuse peripheral opacity (“crazy paving”) compatible with COVID-19–related lesions (Figure 1).
Figure 1

Chest Radiograph and Axial Unenhanced Chest Computed Tomography Scan Obtained on Day 2 After the Onset of Symptoms

(A) Chest X-ray and (B) axial unenhanced chest computed tomography scan. Presence of diffuse typical COVID-19–related lesions (typical peripheral opacity, “crazy paving”). COVID-19 = coronavirus disease 2019.

Chest Radiograph and Axial Unenhanced Chest Computed Tomography Scan Obtained on Day 2 After the Onset of Symptoms (A) Chest X-ray and (B) axial unenhanced chest computed tomography scan. Presence of diffuse typical COVID-19–related lesions (typical peripheral opacity, “crazy paving”). COVID-19 = coronavirus disease 2019. On day 3 of his admission, he presented acute respiratory distress with severe hypoxemia and his oxygen saturations decreased to 82%. The patient was agitated and demonstrated neurological signs, which is why he was intubated under general anesthesia. Prior to intubation, arterial gas analysis showed pH of 7.27, oxygen partial pressure of 51 mm Hg, carbon dioxide partial pressure of 46 mm Hg, and high lactate (14 mmol/l; 0.4 to 2.2 mmol/l). Initially, the patient required 100% oxygen concentration and 15 cm H2O positive expiratory pressure without being in the prone position. Laboratory tests showed very high levels of troponin (11,716 IU/ml), N-terminal pro-type natriuretic peptide (11,719 pg/ml), fibrinogen of 9.5 g/l, peak creatine kinase 2216 IU/l, and C-reactive protein 351 mg/l (N = <5). Electrocardiogram demonstrated sinus tachycardia (120 beats/min) with negative T waves from V2 to V4 (Figure 2). The left ventricle (LV) was mildly enlarged (32 mm/m2 end-diastolic diameter) on echocardiography with increased LV wall thickness (interventricular septum and posterior walls of 14 mm) and marked diffuse hypokinesis (ejection fraction [EF] 30% using biplane Simpson’s method).
Figure 2

Electrocardiogram on Day 1

Sinus tachycardia (100 beats/min) with negative T waves from V2 to V4.

Electrocardiogram on Day 1 Sinus tachycardia (100 beats/min) with negative T waves from V2 to V4. Following the intubation, there was a rapid and significant respiratory and hemodynamic improvement along with adequate diuresis, allowing spontaneous breathing and extubation on day 5. After extubation, echocardiography demonstrated E/e’ ratio suggestive of elevated LV filling pressures. Cardiovascular magnetic resonance was performed on Day 7 and Day 14 with the same protocol. On the first scan, standard cine steady-state free precession showed increased LV wall thickness (14 mm), increased LV volumes (LV tele-diastolic index 127 ml/m2; N = <100) with marked diffuse hypokinesis (left ventricular ejection fraction [LVEF] 33% from the stack of short-axis LV views), and mild pericardial effusion (Videos 1A, 1B, and 1C). Short-tau inversion recovery images indicated marked extensive hypersignal of the LV basal posterolateral wall (Figure 3) indicative of myocardial edema. Dynamic myocardial perfusion images acquired immediately after the injection of 0.1 mmol/l gadolinium chelates showed no perfusion defects. SSFP cines acquired within 2 min after contrast indicated early gadolinium enhancement (EGE) of the LV basal posterolateral wall indicating hyperemia (Figure 3). Late gadolinium enhancement (LGE) images demonstrated nodular subepicardial enhancement of the LV basal posterolateral wall (Figure 3). The diagnosis of acute myocarditis was confirmed by the presence of the 3 major Lake Louise criteria (1). Native T1 and T2 maps of the LV myocardium were acquired in short-axis views through the modified Look-Locker inversion-recovery sequence (Figure 4). Native T1 of the LV myocardium was 1,102 ms in the anteroseptal and 1,209 ms in the posterolateral walls (57 ms and 69 ms for T2, respectively). The mean extracellular volume fraction of the LV myocardium was 33% in the anteroseptal and 39% in the posterolateral walls (N = 20 to 23).
Online Video 1A
Online Video 1B
Online Video 1C
Figure 3

Cardiac Magnetic Resonance: Evolution Between Day 7 and Day 14

Improvement of LV function is shown on cines in the 2CH view, along with a decrease of myocardial edema on T2-weighted STIR (arrows), a decrease of EGE (arrows), and only minor and stable tissue damage on LGE (arrows). 2CH = 2-chamber; EGE = early gadolinium enhancement; LGE = late gadolinium enhancement; LV = left ventricular; STIR = short-tau inversion recovery.

Figure 4

Cardiac Magnetic Resonance: Evolution of T1, T2, and ECVs Between Day 7 and Day 14

Myocardial T2 was increased in the posterolateral wall on Day 7, indicating the presence of edema and it decreased on Day 14. T1 times were higher on Day 7 because of edema. ECV maps depict the dramatic decrease of ECV in the posterolateral wall on Day 14 from 39% to 27%. ECV = extracellular volume.

Cardiac Magnetic Resonance Day 7 Compressed-sensing cine SSFP in the 2-CH view (A), 3-CH view (B), and 4-CH view (C) showing increased LV wall thickness (14 mm), increased LV volumes (LV tele-diastolic index 127 ml/m2; N < 100), and marked diffuse hypokinesis (LVEF 33%). Cardiac Magnetic Resonance Day 7 Compressed-sensing cine SSFP in the 2-CH view (A), 3-CH view (B), and 4-CH view (C) showing increased LV wall thickness (14 mm), increased LV volumes (LV tele-diastolic index 127 ml/m2; N < 100), and marked diffuse hypokinesis (LVEF 33%). Cardiac Magnetic Resonance Day 7 Compressed-sensing cine SSFP in the 2-CH view (A), 3-CH view (B), and 4-CH view (C) showing increased LV wall thickness (14 mm), increased LV volumes (LV tele-diastolic index 127 ml/m2; N < 100), and marked diffuse hypokinesis (LVEF 33%). Cardiac Magnetic Resonance: Evolution Between Day 7 and Day 14 Improvement of LV function is shown on cines in the 2CH view, along with a decrease of myocardial edema on T2-weighted STIR (arrows), a decrease of EGE (arrows), and only minor and stable tissue damage on LGE (arrows). 2CH = 2-chamber; EGE = early gadolinium enhancement; LGE = late gadolinium enhancement; LV = left ventricular; STIR = short-tau inversion recovery. Cardiac Magnetic Resonance: Evolution of T1, T2, and ECVs Between Day 7 and Day 14 Myocardial T2 was increased in the posterolateral wall on Day 7, indicating the presence of edema and it decreased on Day 14. T1 times were higher on Day 7 because of edema. ECV maps depict the dramatic decrease of ECV in the posterolateral wall on Day 14 from 39% to 27%. ECV = extracellular volume.

Management

The patient was treated with paracetamol (3 g/day), hydroxychloroquine (400 mg daily), and 2 l/min nasal oxygen. Then, he was treated with 1 mg/h noradrenalin because of severe hypotension (75/45 mm Hg) and antibiotics (intravenous cefotaxime and rovamycine).

Discussion

Clinical and diagnostic features associated with COVID-19 are mostly respiratory infections, and the most frequent complications are severe pneumonia and acute respiratory distress syndrome (2, 3, 4). We report the case of a young male without comorbidity who presented fulminant myocarditis very early during the course of COVID-19 pneumonia. COVID-19 SARS has been associated with tachyarrhythmia or even heart failure (5). During the current global pandemic, acute myocarditis has been reported in a patient infected by COVID-19 with moderate heart failure and no signs of upper respiratory tract infection (6). This case provided evidence of cardiac involvement as a possible late complication of the respiratory infection and suggested that a secondary exaggerated inflammatory response could be responsible for acute myocarditis (6). We describe fulminant myocarditis occurring early during the course of a COVID-19 pneumonia. The rapid and spectacular improvement of the respiratory function observed is very uncommon and has not been reported with SARS–CoV-2. The elevated LV filling pressures and rapid improvement of respiratory and hemodynamic conditions suggest that acute respiratory and circulatory failures might be caused by acute LV dysfunction and cardiogenic pulmonary edema. This simultaneous presentation of fulminant myocarditis and COVID-19 pneumonia favors an alternative pathogenetic pathway with possible acute replication and direct dissemination of the virus through the blood or the lymphatic system from the respiratory tract to the myocardium (7). In support, a potential binding to a viral receptor of the myocyte could facilitate the internalization and replication of the capsid proteins and the viral genome (8,9). Because of the rapid clinical recovery of the patient, endomyocardial biopsy was not performed and the presence of the coronavirus in the myocardium was not demonstrated.

Follow-Up

Cardiac magnetic resonance on Day 14 showed a significant LV reverse remodeling (wall thickness 11 mm, LV telediastolic index 88 ml/m2, and LVEF 54%) (Videos 2A, 2B, and 2C), a clear decrease of focal myocardial edema and EGE in the posterolateral wall, and stable LGE lesions in the subepicardium of the posterolateral wall (Figure 3). The evolution of native T1 to T2 relaxation times and extracellular volume are reported in Table 1. The patient had complete clinical recovery with normal respiratory function and hemodynamics, and was discharged on Day 15 with bisoprolol and angiotensin-converting enzyme inhibitors.
Online Video 2A
Online Video 2B
Online Video 2C
Table 1

Evolution of T1 and T2 Relaxation Times of the Myocardium and ECV

Native T1 (ms)
T1 Post-Gadolinium (ms)
T2 (ms)
ECV (%)
ASPLASPLASPLASPL
Day 71,1021,20962564857693339
Day 141,0281,05051651949573127

AS = anteroseptal wall; ECV = extracellular volume fraction; PL = posterolateral wall.

Cardiac Magnetic Resonance Day 14 Compressed-sensing cine SSFP in the 2-CH view (A), 3-CH view (B), and 4-CH view (C) showing a significant LV reverse remodelling (wall thickness 11 mm, LV telediastolic index 88 ml/m2, LVEF 54%). Cardiac Magnetic Resonance Day 14 Compressed-sensing cine SSFP in the 2-CH view (A), 3-CH view (B), and 4-CH view (C) showing a significant LV reverse remodelling (wall thickness 11 mm, LV telediastolic index 88 ml/m2, LVEF 54%). Cardiac Magnetic Resonance Day 14 Compressed-sensing cine SSFP in the 2-CH view (A), 3-CH view (B), and 4-CH view (C) showing a significant LV reverse remodelling (wall thickness 11 mm, LV telediastolic index 88 ml/m2, LVEF 54%). Evolution of T1 and T2 Relaxation Times of the Myocardium and ECV AS = anteroseptal wall; ECV = extracellular volume fraction; PL = posterolateral wall.

Conclusions

This report demonstrates that fulminant myocarditis may occur during the acute phase of COVID-19 pneumonia and suggests a direct pathogenic role of the virus on the myocyte, although this has not been proven using histopathology. We believe this finding may have important implications for diagnostic and monitoring purposes, but also for the evaluation of future treatment strategies of acute myocarditis related to SARS-CoV infection.
  7 in total

1.  Advances in the understanding of myocarditis.

Authors:  P P Liu; J W Mason
Journal:  Circulation       Date:  2001-08-28       Impact factor: 29.690

2.  Cardiovascular magnetic resonance in myocarditis: A JACC White Paper.

Authors:  Matthias G Friedrich; Udo Sechtem; Jeanette Schulz-Menger; Godtfred Holmvang; Pauline Alakija; Leslie T Cooper; James A White; Hassan Abdel-Aty; Matthias Gutberlet; Sanjay Prasad; Anthony Aletras; Jean-Pierre Laissy; Ian Paterson; Neil G Filipchuk; Andreas Kumar; Matthias Pauschinger; Peter Liu
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

Review 3.  Molecular biology and pathogenesis of viral myocarditis.

Authors:  Mitra Esfandiarei; Bruce M McManus
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

4.  Cardiovascular complications of severe acute respiratory syndrome.

Authors:  C-M Yu; R S-M Wong; E B Wu; S-L Kong; J Wong; G W-K Yip; Y O Y Soo; M L S Chiu; Y-S Chan; D Hui; N Lee; A Wu; C-B Leung; J J-Y Sung
Journal:  Postgrad Med J       Date:  2006-02       Impact factor: 2.401

5.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).

Authors:  Riccardo M Inciardi; Laura Lupi; Gregorio Zaccone; Leonardo Italia; Michela Raffo; Daniela Tomasoni; Dario S Cani; Manuel Cerini; Davide Farina; Emanuele Gavazzi; Roberto Maroldi; Marianna Adamo; Enrico Ammirati; Gianfranco Sinagra; Carlo M Lombardi; Marco Metra
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

6.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

7.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

  7 in total
  13 in total

1.  Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in Adults.

Authors:  Petra Barhoum; Marc Pineton de Chambrun; Karim Dorgham; Mathieu Kerneis; Sonia Burrel; Paul Quentric; Christophe Parizot; Juliette Chommeloux; Nicolas Bréchot; Quentin Moyon; Guillaume Lebreton; Samia Boussouar; Matthieu Schmidt; Hans Yssel; Lucie Lefevre; Makoto Miyara; Jean-Luc Charuel; Stéphane Marot; Anne-Geneviève Marcelin; Charles-Edouard Luyt; Pascal Leprince; Zahir Amoura; Gilles Montalescot; Alban Redheuil; Alain Combes; Guy Gorochov; Guillaume Hékimian
Journal:  J Am Coll Cardiol       Date:  2022-07-26       Impact factor: 27.203

Review 2.  Cardiovascular manifestations secondary to COVID-19: A narrative review.

Authors:  C Fauvel; A Trimaille; O Weizman; T Pezel; D Mika; V Waldmann; A Cohen; G Bonnet
Journal:  Respir Med Res       Date:  2022-05-04

Review 3.  Cardiovascular Complications in Major 21st Century Viral Epidemics and Pandemics: an Insight into COVID-19.

Authors:  Muzna Hussain; Patrick Collier; Rohit Moudgil
Journal:  Curr Cardiol Rev       Date:  2021

4.  Cardiovascular impact of COVID-19 with a focus on children: A systematic review.

Authors:  Moises Rodriguez-Gonzalez; Ana Castellano-Martinez; Helena Maria Cascales-Poyatos; Alvaro Antonio Perez-Reviriego
Journal:  World J Clin Cases       Date:  2020-11-06       Impact factor: 1.337

Review 5.  Coronavirus Disease 2019 and Heart Failure: A Multiparametric Approach.

Authors:  Estefania Oliveros; Yevgeniy Brailovsky; Paul Scully; Evgenia Nikolou; Ronak Rajani; Julia Grapsa
Journal:  Card Fail Rev       Date:  2020-08-14

Review 6.  Impact of Preinfection Left Ventricular Ejection Fraction on Outcomes in COVID-19 Infection.

Authors:  Daniel P Morin; Marc A Manzo; Peter G Pantlin; Rashmi Verma; Robert M Bober; Selim R Krim; Carl J Lavie; Salima Qamruddin; Sangeeta Shah; José D Tafur Soto; Hector Ventura; Eboni G Price-Haywood
Journal:  Curr Probl Cardiol       Date:  2021-03-19       Impact factor: 5.200

7.  SARS-Cov-2 fulminant myocarditis: an autopsy and histopathological case study.

Authors:  Guillaume Gauchotte; Véronique Venard; Michaël Segondy; Cyril Cadoz; Aude Esposito-Fava; Damien Barraud; Guillaume Louis
Journal:  Int J Legal Med       Date:  2021-01-03       Impact factor: 2.686

Review 8.  Clinical variants of myocardial involvement in COVID-19-positive patients: a cumulative experience of 2020.

Authors:  Maya Guglin; Kareem Ballut; Onyedika Ilonze; Mark Jones; Roopa Rao
Journal:  Heart Fail Rev       Date:  2021-07-02       Impact factor: 4.654

9.  The COVID-19 Pandemic and Cardiovascular Complications: What Have We Learned So Far?

Authors:  Mary Norine Walsh; Antonio Sorgente; David L Fischman; Eric R Bates; Julia Grapsa
Journal:  JACC Case Rep       Date:  2020-06-15

10.  Sudden cardiogenic shock mimicking fulminant myocarditis in a surviving teenager affected by severe acute respiratory syndrome coronavirus 2 infection.

Authors:  Giovanni Garau; Sabrina Joachim; Guy-Loup Duliere; Maria Melissopoulou; Sandrine Boccar; Vincent Fraipont; Christophe Dugauquier; Pierre Troisfontaines; Olivier Hougrand; Philippe Delvenne; Etienne Hoffer
Journal:  ESC Heart Fail       Date:  2020-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.